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ABSTRACT
This study evaluated retrospectively the efﬁcacy of treatment with cefepime vs. a carbapenem, in
combination with amikacin or ciproﬂoxacin, for seriously-ill patients infected with ESBL-producing
Enterobacter aerogenes who were admitted to an intensive care unit. Forty-four episodes of infection
were investigated in 43 patients: 21 treated with cefepime; 23 with a carbapenem. The two treatment
groups did not differ statistically in terms of age, APACHE II scores, and infection sites, but the
average duration of antibiotic exposure was signiﬁcantly shorter in the cefepime group (8.5 days vs.
11.4 days; p 0.04). Clinical improvement was seen in 62% of patients receiving cefepime vs. 70% of
patients receiving a carbapenem (p 0.59). Bacteriological eradication was achieved in 14% of patients
receiving cefepime vs. 22% of patients receiving a carbapenem (p 0.76). The 30-day mortality rates
related to infection were 33% in the cefepime group and 26% in the carbapenem group (p 0.44).
Thus, outcome parameters did not differ signiﬁcantly between the two groups. Nevertheless, a
statistically signiﬁcant increase in failure to eradicate ESBL-producing E. aerogenes was observed as
the MICs of cefepime rose (p 0.017). Pulsed-ﬁeld gel electrophoresis revealed three distinct clones,
but one predominant clone harbouring the blaTEM-24 gene was associated with most (42 ⁄ 44) of the
episodes of infection. It was concluded that cefepime may be an alternative agent for therapy of
severe infections caused by TEM-24 ESBL-producing E. aerogenes, although further studies are
required to conﬁrm these observations.
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INTRODUCTION
Plasmid-mediated extended-spectrum b-lacta-
mases (ESBLs) were ﬁrst reported in the mid-
1980s [1,2], and have since been responsible for
many hospital outbreaks caused by expanded-
spectrum cephalosporin-resistant Enterobacteria-
ceae. The organisms involved most frequently are
Klebsiella pneumoniae and Escherichia coli, and
b-lactamases of the TEM, SHV and CTX-M fam-
ilies are the most common ESBLs found in these
species [3]. These enzymes have also been repor-
ted in inducible AmpC b-lactamase-producing
members of the family Enterobacteriaceae, such
as Enterobacter spp., Citrobacter freundii,Morganella
morganii and Serratia spp. [4,5].
Cefepime is a fourth-generation cephalosporin
with a broader spectrum and greater potency than
other cephalosporins. The drug penetrates more
rapidly into Gram-negative bacteria, targets mul-
tiple essential penicillin-binding proteins, and is
relatively resistant to inactivation by many
b-lactamases because of the low afﬁnity of these
enzymes for cefepime. However, the value of
cefepime in treating infections caused by ESBL-
producing inducible Enterobacteriaceae, such as
Enterobacter spp., is currently unknown as there
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are few clinical data that address this issue. At
present, carbapenems are considered the treat-
ment of choice for these infections [6].
The present study describes a retrospective
cohort study to evaluate the effect of cefepime on
the outcome of infections caused by ESBL-produ-
cing Enterobacter aerogenes. To assess the efﬁcacy of
this drug, comparative studies should include at
least one currentlymarketed group of antibiotics to
which the infecting organisms are susceptible. For
this reason, carbapenems were chosen as the
comparator agents, since they are active against
ESBL-producing Enterobacter spp., and clinical
trials have demonstrated their potency [6]. The
endpoints of evaluation were microbiological and
clinical outcome, and selection of resistance. An
attempt was also made to determine the effect of
combination therapy with either an aminoglyco-
side, amikacin or a ﬂuoroquinolone (ciproﬂoxacin)
on the outcome of infection with ESBL-producing
E. aerogenes strains.
MATERIALS AND METHODS
Hospital setting, study design and deﬁnitions
The study was performed at a 30-bed multidisciplinary
intensive care unit (ICU) at the University Hospital of
Antwerp. The study database was assembled from the records
of patients hospitalised in the ICU between 1 January 1994 and
31 December 2000. Data were selected from administrative,
laboratory and pharmacy databases. The study was designed
as a retrospective cohort study; therefore, the patients’ physi-
cians, not the researchers, determined the antimicrobial ther-
apy regimens. Cefepime (typical dose, 2 g every 8 h, was
utilised for the empirical treatment of suspected nosocomial
Gram-negative bacterial infections at the ICU. Imipenem
(typical dose, 0.5 g every 6 h), replaced in June 1998 by
meropenem (typical dose, 1 g every 8 h), was prescribed for
the empirical treatment of suspected nosocomial multiresistant
Gram-negative bacterial infections. Empirical treatment of
nosocomial infections caused by Gram-negative organisms
was generally in combination with amikacin (typical dose,
15 mg ⁄ kg every 24 h), or ciproﬂoxacin for patients with renal
insufﬁciency (typical dose, 400 mg every 12 h). In general, the
dosage of each antibiotic mentioned was adapted to the renal
function of each individual patient. ‘Nosocomially-acquired
infection’ was deﬁned as an infection that occurred >48 h after
hospital admission [7]. The clinical outcome of patients
infected solely with E. aerogenes and treated with cefepime or
a carbapenem (meropenem ⁄ imipenem) for at least 72 h was
evaluated retrospectively.
The laboratory database was searched to identify all
patients with infections caused by ESBL-producing E. aero-
genes [8], and the pharmacy database was then searched to
identify the subset of patients who were treated with cefepime
or a carbapenem. ‘Therapeutic administration’ of cefepime or
carbapenems was deﬁned as treatment for at least 72 h during
the ﬁrst 5 days after the ﬁrst positive culture of an ESBL-
producing E. aerogenes. Site of infection was recorded as lower
respiratory tract, urinary tract, intra-abdominal or primary
bloodstream, according to CDC deﬁnitions [7].
Data collection
Clinical data collected on study subjects included demo-
graphics (age and gender), disease severity [9], number of
days in the ICU, antimicrobial exposure, renal function at
initiation of therapy, dosage of antibiotics, concomitant
antibiotics, modiﬁcation of antibiotic therapy (and the reason
for this), organisms identiﬁed, specimen type or source and
collection date.
Bacterial characterisation
ESBL production was detected routinely by means of the
double-disk synergy test, with Mueller-Hinton agar and
amoxycillin ⁄ clavulanic acid and cefepime disks [8]. All
ESBL-producing E. aerogenes isolated between January 1994
and December 2000 from patients hospitalised in the ICU were
stored at )70 C. MICs of ceftazidime (GlaxoSmithKline,
Genval, Belgium), cefepime (Bristol-Myers Squibb, Braine-
l’Alleud, Belgium), imipenem (Merck Sharpe & Dohme,
Brussels, Belgium), meropenem (AstraZeneca, Brussels,
Belgium), ciproﬂoxacin (Bayer, Leverkusen, Germany) and
amikacin (Bristol-Myers Squibb) were determined by agar
dilution, according to NCCLS guidelines [10], for 44 initial and
29 subsequent isolates of ESBL-producing E. aerogenes.
The 73 ESBL-positive E. aerogenes isolates (ﬁrst and subse-
quent isolates) were typed by pulsed-ﬁeld gel electrophoresis
(PFGE). Total DNA preparations embedded in agarose plugs
were digested with 50 U XbaI (MBI Fermentas, St. Leon-Rot,
Germany) and separated in agarose 1% w ⁄v gels in a CHEF
Mapper (Bio-Rad Laboratories, Nazareth, Belgium) in
0.5 · TBE buffer (1 · TBE is 89 mM Tris-borate, 1 mM EDTA)
at 14 C for 24 h at a constant voltage of 6 V ⁄ cm. Pulse times
were ramped linearly from 5 to 35 s. Control strains included
two Belgian epidemic strains. Interpretation of banding pat-
terns was based on published criteria [11].
Ten ESBL-producing isolates belonging to different PFGE
types, and with a wide range of MICs, were characterised
further. Ceftazidime resistance transfer was performed as
described previously [12], with selection of transconjugants
on MacConkey agar (Oxoid, Basingstoke, UK) containing
rifampicin (Polfa, Tarchomin, Warsaw, Poland) 128 mg ⁄L
and ceftazidime 2 mg ⁄L. b-Lactamases from clinical isolates
and transconjugants were visualised by isoelectric focusing
(IEF), and their cefotaxime- and ceftazidime-hydrolysing
activities were detected by bioassay, as described by Bau-
ernfeind et al. [13]. Each of the two cephalosporins was used
at a concentration of 2 mg ⁄L. PCR detection and sequencing
of blaTEM and blaSHV genes were performed as described
previously [12,14]. Total DNA from the isolates or their
transconjugants was puriﬁed with a Genomic DNA Prep
Plus kit (A & A Biotechnology, Gdansk, Poland), and the
entire coding regions of the blaTEM and blaSHV genes were
ampliﬁed by PCR. Speciﬁc PCR products were puriﬁed with
a QIAQuick Puriﬁcation kit (Qiagen, Hilden, Germany) and
subjected to direct DNA sequencing with an ABI PRISM 310
automated sequencer (Applied Biosystems, Foster City, CA,
USA). Plasmid ﬁngerprinting was performed as described
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previously [14]. Brieﬂy, plasmid DNA was puriﬁed from
transconjugants by the alkaline method with a Plasmid Midi
kit (Qiagen) and was digested with PstI (MBI Fermentas,
Vilnius, Lithuania).
Outcome measures
The clinical outcome was assessed by an investigator who
was not aware of the antibiotic regimen. Clinical outcome
was classiﬁed as cure, improvement, failure or presumed
failure. ‘Cure’ was deﬁned as a return to the pre-infection
state. ‘Improvement’ was deﬁned as clinical improvement
with residual signs and symptoms of infection which did
not warrant further antibiotic treatment. Subjective parame-
ters were symptoms proper to the location of infection,
while objective parameters were temperature and C-reactive
protein (CRP) levels. ‘Failure’ was deﬁned as persistence or
progression of signs and symptoms, despite treatment for
72 h with cefepime or a carbapenem, that led to an
alteration in antibiotic regimen or death within 30 days of
infection because of an ESBL-producing E. aerogenes. ‘Pre-
sumed failure’ was deﬁned as a situation where the patient
did not die as a clear result of the infection, but where
infection parameters had not improved by the time of death.
Whether mortality was all-cause death or related to infection
was assessed by looking for signs of sepsis or septic shock
within 28 days of the date of the ﬁrst culture with ESBL-
producing E. aerogenes; i.e., fever (>38C) or hypothermia
(<36C), tachycardia (>90 beats ⁄min), tachypnoea (>20
respirations ⁄min), leukocytosis (>12 000 cells ⁄mm3) or leu-
kopenia (<4000 cells ⁄mm3), a failing organ system (kidney,
lungs, heart, liver, central nervous system, coagulation),
hypoperfusion or hypotension (systolic blood pressure
<90 mmHg or a reduction of >40 mmHg from baseline)
and use of inotropic ⁄vasopressor drugs [15].
Microbiological outcome was classiﬁed as eradication,
persistence, presumed persistence or unknown. ‘Eradication’
was deﬁned as elimination of the causative organism from
the initial culture site at the time of completion of therapy.
‘Persistence’ was deﬁned as failure to eradicate the causative
organism from the previous culture site, based on typing by
PFGE, regardless of clinical outcome. The term ‘presumed
persistence’ was used when the causative organism persisted
at the initial culture site, but the organism was not available
for typing by PFGE. Isolation of the same PFGE clone of
ESBL-producing E. aerogenes at the initial culture site
>1 week after the end of therapy was also recorded as
‘presumed persistence’. When no bacteriological follow-up
cultures were available after the start of therapy, the
bacteriological outcome was recorded as ‘unknown’.
‘Emergence of resistance’ was recorded when there was a
greater than two-fold increase in MIC for an ESBL-producing
E. aerogenes organism that belonged to the same PFGE clone as
an initial isolate.
Statistical analysis
Statistical analysis was performed with SPSS software (SPSS
Inc., Chicago, IL, USA). A two-sided test with p < 0.05 was
considered to be signiﬁcant. The unpaired student t-test was
used for comparing continuous variables, and the Chi-Square
test was used for categorical variables. To compare MICs of
cefepime and meropenem for isolates from patients with
favourable vs. unfavourable bacteriological outcome, clinical
outcome and 30-day mortality vs. survival, a two-sided Mann–
Whitney U-test was used.
RESULTS
Characteristics of the total patient population
In total, 43 patients (44 episodes) were eligible for
study by virtue of an infection with ESBL-produ-
cing E. aerogenes that was treated with cefepime
(21 episodes) or a carbapenem (23 episodes; 12
episodes treated with imipenem and 11 episodes
treated with meropenem) (Table 1). Nineteen
patients (44%) died during their stay in the ICU,
with 13 (68%) deaths being related to infection.
Twenty-nine episodes (66%) of ESBL-positive
E. aerogenes infection showed cure or clinical
improvement at the end of therapy; the bacteria
were eradicated in eight episodes (18%). Among
25 episodes with cure or improvement, the
organism was eradicated in seven cases, whereas
in 11 episodes of infection with no improvement,
the bacteria persisted in ten cases (not signiﬁcant).
In 40 of the 44 episodes of infection involving an
ESBL-positive E. aerogenes, the patients had been
intubated before therapy started; in 38 episodes,
the patients had received antimicrobial therapy
(for a period of 1–14 days) preceding their infec-
tion.
Comparison of groups and outcome parameters
There were no statistically signiﬁcant differences
in the outcome parameters for the cefepime-
and carbapenem-treated groups (Table 2). The
Table 1. Characteristics of patients with ESBL-producing
Enterobacter aerogenes infection
Patient characteristic Cefepime groupa Carbapenem groupa p
Number of patients 21 22
Number of episodes 21 23
Mean age, ± SD (years) 59.7 ± 19.7 64.2 ± 13.6 0.379
Mean Apache II score ± SD 21.0 ± 7.5 17.9 ± 6.6 0.185
Mean creatinine, ± SD (mg ⁄dL) 2.1 ± 2.0 1.6 ± 1.6 0.315
Mean antibiotic
duration ± SD (days)
8.5 ± 3.9 11.4 ± 5.0 0.040
Combination with
Amikacin 12 (57%) 17 (74%)
Ciproﬂoxacin 5 (24%) 1 (4%)
Site of infection
Lower respiratory tract 14 (66%) 14 (61%)
Bloodstream 2 (10%) 5 (22%)
Urinary tract 2 (10%) 0 (0%)
Mediastinitis 0 (0%) 1 (4%)
Intra-abdominal 3 (14%) 3 (13%)
ESBL, extended-spectrum b-lactamase. aNumber (%) of case episodes, except as
indicated.
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relationship between independent patient charac-
teristics (age, APACHE II scores and duration of
therapy) and outcome measures was assessed,
but no signiﬁcant relationship with bacteriologi-
cal outcome measures was found; only age was
related signiﬁcantly to clinical outcome and
30-day mortality (p < 0.05) (data not shown).
Susceptibility of ESBL-producing E. aerogenes
isolates
Bacteriological outcome, clinical outcome and 30-
day mortality in relation to MIC were analysed
for patients treated with cefepime (Table 3) and
those treated with carbapenems (Table 4). In the
cefepime group, there was a statistically signiﬁ-
cant increase in bacteriological failure to eradicate
the ESBL-producing E. aerogenes as MICs of
cefepime rose (p 0.017). In the carbapenem group,
MICs of meropenem did not differ signiﬁcantly
between eradicated and persisted ⁄presumed
persisted infection with ESBL-producing E. aero-
genes, clinically improved and failed ⁄presumed
failed patients, and those who survived or died of
the infection.
Selection of resistance was observed in one
patient infected with an E. aerogenes isolate har-
bouring a TEM-24 variant, which was classiﬁed in
PFGE clone A. The patient was treated for
nosocomial pneumonia with cefepime in combi-
nation with amikacin for 14 days; the MIC of
cefepime for the isolate 1 day before treatment
was 2 mg ⁄L, which increased to >32 mg ⁄L at
6 days after the end of therapy; the MIC of
meropenem also increased from 0.06 to 4 mg ⁄L;
the MIC of amikacin remained constant at
8 mg ⁄L. In one patient treated with imipenem,
the MIC of imipenem increased from 0.25 to
8 mg ⁄L (although the organism persisted, the
patient was classiﬁed as cured), and in a second
patient, treated with meropenem, the MIC of
meropenem increased from 0.5 to 4 mg ⁄L (again,
the patient showed a clinical improvement
although the organism persisted).
Evaluation of antibiotic combination therapy
Outcome measures for cefepime in combination
with amikacin vs. a combination with an antibi-
otic not active against the ESBL-producing E. aero-
genes isolates did not differ signiﬁcantly (Table 5).
PFGE typing
Among the 44 initial isolates causing infection,
PFGE revealed three distinct clones: A, 42 isolates;
B, one isolate; and C, one isolate (data not shown).
Clone A clustered with the Belgian epidemic type
Table 2. Outcome measures for 44 episodes of infection
with ESBL-producing Enterobacter aerogenes
Outcome measure
Number (%) of case episodes
p
Cefepime group
(21 episodes)
Carbapenem group
(23 episodes)
Mortality 0.437
Death related to infection 7 (33%) 6 (26%)
Death by other causes 4 (19%) 2 (9%)
Survival 10 (48%) 15 (65%)
Clinical outcome 0.592
Cured + improved 13 (62%) 16 (70%)
(Presumed) failure 8 (38%) 7 (30%)
Bacteriological outcome 0.762
Eradicated 3 (14%) 5 (22%)
Persisted 9 (43%) 7 (30%)
Presumed persisted 6 (29%) 6 (26%)
Unknown 3 (14%) 5 (22%)
ESBL, extended-spectrum b-lactamase.
Table 3. Relationship between cefe-
pime MIC and outcome measures in
the cefepime-treated group of
patients MIC (mg ⁄L)
of cefepime
Bacteriological outcome Clinical outcome 30-day mortality
Eradicated
Presumed
persisted
and persisted
Cured and
Improved
Presumed
failure
and failure Survival
All-cause
death
£0.125 0 0 0 0 0 0
0.25 1 0 1 0 1 0
0.5 0 1 1 0 1 0
1 2 1 2 1 3 0
2 0 7 3 5 1 7
4 0 2 2 1 1 2
8 0 0 0 0 0 0
16 0 0 0 0 0 0
32 0 3 2 1 2 1
>32 0 1 2 0 1 1
Median 1 2 2 2 1 2
Range 0.25–1 1–>32 0.25–>32 1–32 0.25–>32 2–>32
p 0.017 0.017 0.793 0.793 0.308 0.308
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1 (BE 1), and clone B clustered with the Belgian
epidemic type 2 (BE 2).
ESBL characterisation
The IEF and bioassay analyses revealed that eight
isolates belonging to PFGE clones A and B, as well
as their transconjugants, produced a cefotaxime-
and ceftazidime-hydrolysing enzyme of pI 6.5
(data not shown). This ESBL was identiﬁed as a
TEM-type b-lactamase by PCR, and sequencing
identiﬁed the enzyme as TEM-24. The two
remaining isolates of PFGE clone C, and their
transconjugants, expressed b-lactamases with pIs
of 8.2 and 5.4, of which only the pI 8.2 enzyme
demonstrated cefotaxime- and ceftazidime-
hydrolysing activity (data not shown). PCR and
sequencing revealed this ESBL to be SHV-12.
Plasmids puriﬁed from the eight TEM-type ESBL-
expressing transconjugants had an identical PstI
restriction pattern, which differed from that of the
plasmids carried by the SHV-12-producing trans-
conjugants (data not shown).
DISCUSSION
Infection with E. aerogenes is difﬁcult to treat
because of intrinsic resistance and rapid devel-
opment of increased resistance. Carbapenems
have been the most successful drugs for the
treatment of infections caused by ESBL-produ-
cing Enterobacteriaceae [6]. The use of cefepime
as an effective therapy for infections caused by
inducible ESBL-producing Enterobacteriaceae,
such as Enterobacter spp., is highly controversial.
In general, cefepime exhibits more stability to
hydrolysis by ESBLs than the earlier cephalo-
sporins [16,17]. An inoculum effect has been
detected consistently with cefepime [18], but
this did not necessarily result in clinical failure
in animal models [19]. Favourable clinical
results in man, however, have not yet been
forthcoming and, more recently, there have been
published case reports describing clinical fail-
ures with this fourth-generation cephalosporin
[20,21].
The present study did not demonstrate signiﬁ-
cant differences in clinical or bacteriological out-
come between cefepime and carbapenems for the
treatment of infections caused by an ESBL-pro-
ducing E. aerogenes in severely-ill patients admit-
ted to an ICU. No signiﬁcant difference was
detected between two groups representing a
patient population divided equally in terms of
infection and patient characteristics, although the
sample size was small. However, this study
describes the largest group of patients ever
reported in which different antibiotic regimens
Table 4. Relationship between mero-
penem MIC and outcome measures in
the carbapenem-treated group
MIC (mg ⁄L)
of meropenem
Bacteriological outcome Clinical outcome 30-day mortality
Eradicated
Presumed
persisted
and persisted
Cured and
Improved
Presumed
failure
and failure Survival
All-cause
death
£0.125 3 7 10 5 9 6
0.25 1 0 1 0 1 0
0.5 1 2 3 0 3 0
1 0 1 1 0 1 0
2 0 1 0 1 0 1
4 0 2 1 1 1 1
8 0 0 0 0 0 0
16 0 0 0 0 0 0
32 0 0 0 0 0 0
>32 0 0 0 0 0 0
Median £0.125 £0.125 £0.125 £0.125 £0.125 £0.125
Range £0.125–0.5 £0.125–4 £0.125–4 £0.125–4 £0.125–4 £0.125–4
p 0.234 0.234 0.773 0.773 0.972 0.972
Table 5. Outcome of combination therapy for patients
treated with cefepime for infections caused by ESBL-
producing Enterobacter aerogenes
Outcome measure
Number (%) of case episodes
treated with cefepime in combi-
nation with
p
Amikacin
(12 episodes)
Ciproﬂoxacina
(9 episodes)
Mortality 0.528
Death (all causes) 7 (58%) 4 (44%)
Survival 5 (42%) 5 (56%)
Clinical outcome 0.697
Cured and improved 7 (58%) 6 (67%)
Failure 5 (42%) 3 (33%)
Bacteriological outcome 0.163
Eradicated 2 (17%) 4 (44%)
Persisted ⁄presumed persisted 10 (83%) 5 (56%)
ESBL, extended-spectrum b-lactamase. aEnterobacter aerogenes isolates resistant.
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have been compared for the treatment of infec-
tions caused by ESBL-producing E. aerogenes.
MICs of cefepime in the cefepime group were a
signiﬁcant prognostic factor for bacteriological
eradication, but not for clinical improvement.
Mimoz et al. [22] demonstrated true synergy for
the combination of cefepime and amikacin against
AmpC-derepressed Enterobacter cloacae strains in a
rat model of pneumonia. The present study
assessed the role of amikacin in combination with
cefepime for the treatment of infections caused by
ESBL-producing E. aerogenes by comparing this
combination with combinations including antibi-
otics (mostly ciproﬂoxacin) that were not active
in vitro against the E. aerogenes isolates, with no
signiﬁcant difference in outcome.
PFGE revealed one major (A) and two minor (B
and C) clones among the E. aerogenes isolates
studied. Characterisation of ESBLs showed that
all PFGE clone A and B isolates harboured TEM-
24, whereas isolates of clone C expressed an SHV-
12 variant. TEM-24 was ﬁrst characterised in 1988
in France as CAZ-6 in a Klebsiella pneumoniae
isolate from the sputum of a patient undergoing
ceftazidime treatment [23]. In 1988 and 1989, this
enzyme was identiﬁed in a large number of
isolates responsible for outbreaks in French ICUs
[24], and was found in 1994 in various species,
particularly E. aerogenes [25]. A nationwide dis-
semination of two epidemic multiresistant E. aero-
genes strains has occurred in Belgian hospitals
since the mid-1990s [26]. The blaTEM-24 gene was
highly prevalent in the Belgian type 1 epidemic
strain (BE1), which appeared to be related to the
epidemic clone producing TEM-24 that was iso-
lated in France [26] and Spain [27]. PFGE analysis
of the E. aerogenes isolates that produced TEM-24
in the present study showed that they were either
indistinguishable or related closely to the BE1
strain. This E. aerogenes clone carrying TEM-24
seems to be well-adapted to the hospital environ-
ment, and has been spreading extensively in at
least three European countries. The second ESBL
identiﬁed in this work, SHV-12, was described
ﬁrst by Nu¨esch-Inderbinen et al. [28] in Switzer-
land in 1997 in Escherichia coli and Klebsiella spp.
[28]. It has subsequently been one of the most
common ESBL variants in Italy, where both
E. cloacae and E. aerogenes isolates with SHV-12
have been observed previously [29]. Selection of
resistance was observed in one patient infected
with an E. aerogenes isolate which belonged to
PFGE clone A and produced a TEM-24 variant.
This patient was treated for nosocomial pneu-
monia with cefepime in combination with amika-
cin for 14 days, which resulted in clinical
improvement despite bacterial persistence.
In conclusion, this study showed that cefepime
in high dosage (2 g every 8 h) might be used
successfully for treatment of serious infections
caused by ESBL-producing E. aerogenes. However,
the results are difﬁcult to extrapolate as a signi-
ﬁcant increase was observed in bacteriological
failure rates as the MIC of cefepime increased, the
sample size was small, most patients were infec-
ted with an E. aerogenes clone producing one
particular ESBL (TEM-24), and the patients were
severely ill with a very high overall mortality rate.
Prospective studies evaluating a larger number of
patients, and which examine whether cefepime
can be used safely as monotherapy, should be
conducted to determine whether this conclusion
can be supported.
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